About Us

Founded in 2018, Rinri Therapeutics Ltd. is a therapeutic discovery and development company working in the field of hearing loss supported by Boehringer Ingelheim and UCB Venture Funds, BioCity and The University of Sheffield.

Rinri Therapeutics has been founded on pioneering research into auditory stem cells led by Professor Marcelo Rivolta at the University of Sheffield.

The Company has a team of experienced management, strong academic pedigree and excellent potential for clinical development.

What is the origin of the name?
‘Rinri’ means ear in Quechua, a language spoken by some of the original people of South America.

Otic Progenitors
Inner ear structure
First in Class

Rinri Therapeutics is focused on exploiting our unique scientific position to develop a cell therapy to functionally restore hearing in people with sensorineural hearing loss.

Rinri Therapeutics’ cell therapy is unique in its ability to replace the dead or damaged specialised sensory cells of the inner ear.

Rinri Therapeutics’ technology is differentiated from other approaches to hearing loss restoration and has the potential to make a significant impact on treatment.